AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This phase III trial is conducted to evaluate if azacitidine in combination with venetoclax
as maintenance therapy improves relapse-free survival (RFS) for younger adults with
favorable-risk acute myeloid leukemia (AML) who remained in first complete remission (CR1)
following intensive consolidation.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University